Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...
Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback